3
likes
0
comments
daily view 0
monthly view 0

Share

Live Analytics

Comments 0

Mesoblast (ASX:MSB, Nasdaq:MESO): Strong growth, Ryoncil momentum and unlocking future opportunities Analytics Table

Income Estimates for Mesoblast (ASX:MSB, Nasdaq:MESO): Strong growth, Ryoncil momentum and unlocking future opportunities

Based on this YouTube video's total view count of 590 views and industry-standard rates, the estimated total earning is $0 - $1 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

About Mesoblast (ASX:MSB, Nasdaq:MESO): Strong growth, Ryoncil momentum and unlocking future opportunities

Explore Mesoblast (ASX:MSB, Nasdaq:MESO): Strong growth, Ryoncil momentum and unlocking future opportunities with 590 views, 3 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

Mesoblast (ASX:MSB, Nasdaq:MESO) has delivered a strong FY2026 result, with Ryoncil® driving a major lift in revenue and the company moving closer to a sustainable commercial model. At the same time, cash discipline has improved while Mesoblast continues to invest in its pipeline and next phase of growth. With Ryoncil® gaining traction, plans to expand into the adult market and its Phase 3 chronic low back pain trial complete, Mesoblast is entering its next stage of growth. Mesoblast CEO and Managing Director Dr Silviu Itescu joins Lel Smits from The Stock Network to discuss the results, Ryoncil® growth and key catalysts ahead. 1. FY26 Financial results highlights You’ve just released your full year results for the 2026 financial year. Can you talk us through the highlights? 2. Ryoncil®: building commercial momentum Ryoncil® generated US$115.2 million in net revenue, with more than 50 U.S. sites onboarded and coverage reaching more than 280 million people. What is driving this growth, and how do you keep the momentum going? 3. Unlocking the adult market Mesoblast is progressing Ryoncil® into adults with severe steroid-refractory acute graft versus host disease, a market three times larger than the paediatric market. How significant could this expansion be, and what are your near term priorities? 4. The next big catalyst The Phase 3 chronic low back pain trial has completed treatment of 350 patients, with results expected in mid-2027. Mesoblast is also advancing its heart failure and next-generation programs. Which upcoming milestone could have the biggest impact on Mesoblast? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _

About YouTube Real-Time View Count

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.

Embed Widget

Parameters:

  • fullscreen=true - Fullscreen counter
  • graph=true - Live graph chart
  • counter=0/1/2 - Select counter (0=likes, 1=views, 2=comments)
URL

Click to copy the embed URL to your clipboard